Cadrenal Therapeutics announces annual shareholder meeting

• Cadrenal Therapeutics will hold its annual shareholder meeting virtually on Sept. 24, 2026.
• Shareholders will vote on the election of a Class I director, with Quang X. Pham nominated for a three-year term.
• Ballot includes a plan to raise the 2022 equity incentive plan share pool by 323,542 shares to 1,000,000 shares.
• Investors will also vote on issuing up to 960,000 shares upon exercise of Series C-1 warrants from a July 1, 2026 private placement.
• Meeting may be adjourned to allow additional solicitation tied to the equity plan amendment or warrant exercise proposals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cadrenal Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-084710), on August 03, 2026, and is solely responsible for the information contained therein.